The mdm2 Proto-Oncogene

References

• Cahilly-Snyder L., Yang-Feng T., Francke U., George D.L. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat. Cell Mol. Genet. 1987; 13: 235–244
   PubMedGoogle Scholar
• Farkharzadeh S.S., Trusko S.P., George D.L. Tumorigenic potential associated with enhanced expression of a gene that is amplified in mouse tumor cell line. EMBOJ. 1991; 10: 1565–1569
   PubMed Web of Science ®Google Scholar
• Gottlieb T.M., Oren M. p53 in growth control and neoplasia. Biochimica et Biophysica Acta 1996; 1287: 77–102
   PubMed Web of Science ®Google Scholar
• Kern S.E., Kinzler K.W., Bruskin A., Jarosz D., Friedman P., Prives C., Vogelstein B. Identification of p53 as a sequence-specific DNA binding protein. Science 1991; 252: 1708–1711
   PubMed Web of Science ®Google Scholar
• Funk W.D., Pak D.T., Karas R.H., Wright W.E., Shay J.W. Transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol. 1992; 12: 2866–2871
   PubMed Web of Science ®Google Scholar
• El-Deiry W.S., Kern S.E., Pietenpol J.A., Kinzler K.W., Vogelstein B. Definition of a consensus binding site for p53. Nature Genet. 1992; 1: 45–49
   PubMed Web of Science ®Google Scholar
• Farmer G.E., Bargonetti J., Zhu H., Friedman P., Prywes R., Prives C. Wild-type p53 activates transcription in vitro. Nature 1992; 358: 83–86
   PubMed Web of Science ®Google Scholar
• Zambetti G.P., Bargonetti J., Walker K., Prives C., Levine A.J. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes and Develop. 1992; 6: 1143–1152
   PubMed Web of Science ®Google Scholar
• El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. Waf, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817–825
   PubMed Web of Science ®Google Scholar
• Okamoto K., Beach D. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J. 1994; 13: 4816–4822
   PubMed Web of Science ®Google Scholar
• Kastan M.B., Zhan Q., el-Deiry W.S., Carrier F., Jacks T., Walsh W.V., Plunkett B.S., Vogelstein H., Fornace A.J., Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71: 587–597
   PubMed Web of Science ®Google Scholar
• Morris G.F., Biwhoff J.R., Mathews M.B. Transcriptional activation of thr human proliferating-cell nuclear antigen promoter by p53. Proc. Natl Acad. Sci. USA 1906; 93: 895–899
   Web of Science ®Google Scholar
• Miyashita T., Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293–290
   PubMed Web of Science ®Google Scholar
• Hinds P.W., Finlay C.A., Quartin K.S., Baker S.J., Fearon E.R., Vogelstein B., Levine A.J. Mutant p53 DNAs from human colorectal carcinomas cooperate with ras in transforming primary rat cells: a comparison of the “hot spot” mutant phenotypes. Cell Growth and Diff. 1990; 1: 571–580
   PubMedGoogle Scholar
• Barak Y., Oren M. Enhanced binding of a 95 Kd protein to p53 in cells undergoing p53-mediated growth arrest. EMBOJ. 1992; 11: 2115–2121
   PubMed Web of Science ®Google Scholar
• Momand J., Zambetti G.P., Olson D., George D.I., Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated trans-activation. Cell 1992; 69: 1237–1245
   PubMed Web of Science ®Google Scholar
• Oliner J.D., Kinzler K.W., Meltrer P.S., George D.L., Vogelstein B. Amplification of a gene ending a p53 associated protein in human sarcomas. Nature 1992; 358: 80–83
   PubMed Web of Science ®Google Scholar
• Oliner J.D., Pietenpol J.A., Thiagalingam S., Gyuris J., Kinzler K.W., Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362: 857–860
   PubMed Web of Science ®Google Scholar
• Chen J., Marechal V., Levine A.J. Mapping of the p53 and mdm2 interaction domains. Mol. Cell. Biol. 1993; 13: 4107–4114
   PubMed Web of Science ®Google Scholar
• Lin J., Chen J., Elenbaas B., Le-Inc A.J. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus S EIB SS-kD protein. Genes and Dev. 1994; 8: 1235–1246
   PubMed Web of Science ®Google Scholar
• Picksley S.M., Vojtesek B., Sparks A., Lane D.P. Immunochemical analysis of the interaction of p53 and mdm2;-fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 1994; 9: 2523–2529
   PubMed Web of Science ®Google Scholar
• Fields S., Jang S.K. Presence of a potent transcription activating sequence in the p53 protein. Science 1990; 249: 1046–1049
   PubMed Web of Science ®Google Scholar
• Zauberman A., Barak Y., Ragimov N., Levy N., Oren M. Sequence-specific binding DNA binding by p53-identification of target sites and lack of binding to p53-Mdm2 complexes. EMBOJ. 1993; 12: 2799–2808
   PubMed Web of Science ®Google Scholar
• Finlay C.A. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol. Cell. Biol. 1993; 13: 301–306
   PubMed Web of Science ®Google Scholar
• Chen J., Wu X., Lin J., Levine A.J. Mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor. Mol. Cell. Biol. 1996; 16: 2445–2452
   PubMed Web of Science ®Google Scholar
• Haupt Y., Barak Y., Oren M. Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J. 1996; 15: 1596–1606
   PubMed Web of Science ®Google Scholar
• Chen C.-Y., Oliner J.D., Zhan Q., Fornace A.J., Jr., Vogelstein, Kastan M.B. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc. Natl. Acad. Sci. USA 1994; 91: 2684–2688
   PubMed Web of Science ®Google Scholar
• Kondo S., Barnett G.H., Hara H., Morimura T., Takeuchi J. MDM2 protein confers resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene 1995; 10: 2001–2006, 1995
   PubMed Web of Science ®Google Scholar
• Barak Y., Juven T., Haffner R., Oren M. mdm2 expression is induced by wild-type p53 activity. EMBO J. 1993; 12: 461–468
   PubMed Web of Science ®Google Scholar
• Wu X., Bayle J.H., Olsun D., Levine A.J. The p53-mdm-2 autoregulatory feedback loop. Genes and Dev. 1993; 7: 1126–1132
   PubMed Web of Science ®Google Scholar
• Juven T., Barak Y., Zauberman A., George D.L., Oren M. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 1993; 8: 3411–3416
   PubMed Web of Science ®Google Scholar
• Barak Y., Gottlieb E., Juven Gershou T., Oren M. Regulation of mdm2 expression by p53: alternative prometters produce transcripts with nonidentical translation potential. Genes and Dev. 1994; 8: 1739–1749
   PubMed Web of Science ®Google Scholar
• Zauberman A., Flusberg D., Haupt Y., Barak Y., Oren M. A functional p53-responsive intronic promoter is contained within the human mdm-2 gene. Nucleic Acids Res. 1995; 23: 2584–2592
   PubMed Web of Science ®Google Scholar
• Perry M.E., Piette J., Zawadzki J.A., Harvey D., Levine A.J. The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc. Natl., Acad, Sci. USA 1993; 90: 11623–11627
   PubMed Web of Science ®Google Scholar
• Allday M.J., Sinclair A., Parker G., Crawlord D.H., Farrell P.J. Epstein-Barr virus efficiently immortalizes human B cells without neutralizing the function of p53. EMBOJ. 1995; 14: 1382–1391
   PubMed Web of Science ®Google Scholar
• Sigalas I., Calvert H.A., Anderson J.J., Neal D.E., Lunec J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer. Nature Medicine 1996; 2: 912–917
   PubMed Web of Science ®Google Scholar
• Sheikh M.S., Shao Z-M., Hussain A., Fontana J.A. The p53-binding protein MDM2 is differentially expressed in human breast carcinoma. Canrer Res. 1993; 53: 3226–3228
   PubMed Web of Science ®Google Scholar
• Gudas J.M., Nguyen H., Klein R.C., Katayose D., Seth P., Cowan K.H. Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells. Clinical Cancer Res. 1995; 1: 71–80
   PubMed Web of Science ®Google Scholar
• Bueso-Ramos C.E., Yang Y., deLeon E., McCown P., Stass S.A., Albitar M. The human MDM-2 oncogene is overexpressed in leukemias. Blood 1993; 82: 2617–2623
   PubMed Web of Science ®Google Scholar
• Quesnel B., Preudhomme C., Oscier D., Lepelley P., Hooghe M., Collyn-d Facon T., Zandecki M., Fenaux P. Over-expression of the MDM2 gene is found in some cases of haematological malignancies. Brit. J. Haematol. 1994; 88: 415–418
   PubMed Web of Science ®Google Scholar
• Watanabe T., Hotta T., Ichikawa A., Kinoshita T., Nagai H., Uchida T., Murate T., Saito H. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 1994; 84: 3158–3165
   PubMed Web of Science ®Google Scholar
• Marks D.I., Kurz B.W., Link M.P., Ng E., Shuster J.J., Lauer S.J., Brodsky I., Haines D.S. High incidence of potential p53 pathway inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis. Blood 1996; 87: 1155–1161
   PubMed Web of Science ®Google Scholar
• Leach F.S., Tokino T., Meltzer, Burrell M., Oliner J.D., Smith S., Hill D.E., Sidransky D., Kinzler K.W., Vogelstein B. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 1993; 53: 2231–2234
   PubMed Web of Science ®Google Scholar
• Ladanyi M., Cha C., Lewis R., Jhanwar S.C., Huvos A.G., Healy J.H. MDM2 gene amplification in met tic osteosarcoma. Cancer Res. 1993; 53: 16–18
   PubMed Web of Science ®Google Scholar
• Reifenberger G., Liu L., Ichimura K., Schmidt E.E., Collins V.P. Amplification and overexpression of the MDM2 gene in a subset ol human gliomas without p53 mutations. Cancer Res 1993; 58: 2736–2139
   Google Scholar
• Ladanyi M., Lewis R., Jhanwar S.C., Gerald W., Huvos A.G., Healey J.H. MDM2 and CDK4 gene amplification in Ewing's sarcoma. J. Pathology 1995; 175: 211–217
   PubMed Web of Science ®Google Scholar
• McCann A.H., Kirley A., Carney D.N., Corbally N., Magee H.M., Keating G., Dervan P.A. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Brit. J. Cancer 1995; 71: 981–985
   PubMed Web of Science ®Google Scholar
• Habuchi T., Kinoshita H., Yamada H., Kakehi Y., Ogawa O., Wu W.J., Takahashi R., Sugiyama T., Yoshida O. Oncogene amplification in urothelial cancers with p53 gene mutations or mdm2 overexpression. J. Natl. Cancer Inst. 1994; 86: 1331–1335
   PubMed Web of Science ®Google Scholar
• Vogelstein B., Kinzler K.W. p53 function and dysfunction. Cell 1992; 70: 523–526
   PubMed Web of Science ®Google Scholar
• Marchetti A., Buttitta F., Pellegrini S., Merlo G., Chella A., Angeletti C.A., Bevilacqau G. mdm2 gene amplification and overexpression in non-small cell lung carcinoma with accumulation of the p53 protein in the absence of p53 gene mutation. Dingnostic Molecular Pathologv 1995; 4: 93–97
   PubMed Web of Science ®Google Scholar
• Gelsleichter L., Gown A.M., Zaro R.J., Wang E., Coltrera M.D. p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm2, and markers of cell proliferation in primary versus metastic tumors. Modern Pathology 1995; 8: 530–535
   PubMed Web of Science ®Google Scholar
• Girod S.C., Cesarz D., Fisher U., Krueger G.R. Detection of p53 and MDM2 protein expression in head and neck carcinogenesis. Anticancer Res 1995; 15: 1453–1457
   PubMed Web of Science ®Google Scholar
• Riou G., Barrois M., Prost S., Terrier M.J., Theodore C., Levine A.J. The p53 and mdm-2 genes in human testicular germ-cell tumors. Molecular Carcinogenesis 1995; 12: 124–131
   PubMed Web of Science ®Google Scholar
• Lianes P., Orlow I., Zhang Z.F., Olivia M.R., Sarkins A.S., Reuter V.E., Cordon-Cardo C. Altered patterns of MDM2 and TPS3 expression in human bladder cancer. J. Natl. Cancer Inst. 1994; 86: 1325–1330
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C., Latres E., Drodnjak M., Olivia M.R., Pollack D., Woodruff J.M., Marechal V., Chen J., Brennan M.F., Levine A.J. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994; 54: 794–799
   PubMed Web of Science ®Google Scholar
• Levine A.J., Momand J., Finlay C.A. The p53 tumour suppressor gene. Nature 1991; 351: 453456
   Web of Science ®Google Scholar
• Chilosi M., Doglioni C., Menestrina F., Montagne L., Rigo A., Lestani M., Barbareschi M., Scarpa A., Mariuzzi G.M., Pizzolo G. Abnormal expression of the p53 binding protein MDM2 in Hodgkin's disease. Blood 1994; 84: 4295–4300
   PubMed Web of Science ®Google Scholar
• Ridge S.A., Dyer M., Greaves M.F., Wiedemann L.M. Lack of MDM2 amplification in human leukaemia. Brit. J. Haematol. 1994; 86: 407–409
   PubMed Web of Science ®Google Scholar
• Maestro R., Gloghini A., Doglioni C., Gasparotto D., Vukosavljevic T., De Re V., Laurino L., Carbone A., Boiocchi M. MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-hodgkin's lymphomas. Blood 1995; 85: 3239–3246
   PubMed Web of Science ®Google Scholar
• Martinez J.C., Mateo M., Sanchez-Beato M., Villuendas R., Orradre J.L., Algara P., Sanchez-Verde L., Garcia P., Lopez C., Martinez P., Paris M.A. MDM2 expression in lymphoid cells and reactive and neoplastic lymphoid tissue. Comparative study with p53 expression. J. Pahology 1995; 177: 27–34
   PubMed Web of Science ®Google Scholar
• Marks D.I., Kurz B.W., Link M.P., Ng E., Shuster J.J., Lauer S.J., Carroll D., Brodsky I., Haines D.S. Altered expression of mdm-2 and p53 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia, Manuscript submitted
   Google Scholar
• Lowe S.W., Bodis S., McClatchey A., Remington L., Ruley H.E., Fisher D.E., Housman D.E., Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807–810
   PubMed Web of Science ®Google Scholar
• Lowe S.W., Ruley H.E., Jacks T., Houseman D.E. p53 dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 80: 957–967
   Web of Science ®Google Scholar
• Livingston L.R., White A., Sprouse J., Livanos E., Jacks T., Tlsty T.D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1993; 70: 923–935
   Web of Science ®Google Scholar
• Sands A.T., Suraokar M.B., Sanchez A., Marth J.E., Donehower L.A., Bradley A. p53 deficiency does not affect the accumulation of point mutations in a transgene target. Proc Natl. Acad. Sci. USA 1995; 92: 8517–8521
   PubMed Web of Science ®Google Scholar
• Thor A.D., Moore D.H., II, Edgerton S.M., Kawasaki E.S., Reihsau E., Lynch H.T., Marcus J.N., Schwartz L., Chen L.C., Mayall B.H., Smith H.S. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancer. J. Natl. Cancer Inst. 1992; 84: 845–855
   PubMed Web of Science ®Google Scholar
• Kovach J.S., Hartmann A., Blaszk H., Cunningham J., Schaid D., Sommer S.S. Mutation detection by highly sensitive methods indicate that p53 gene mutations in breast cancer can have important prognostic value. Proc. Natl. Acad. Sci. USA 1996; 93: 1093–1096
   PubMed Web of Science ®Google Scholar
• Martin H.M., Filipe M.I., Morris R.W., Lane D.P., Silvestre F. p53 expression and prognosis in gastric carcinoma. Int. J. Cancer 1992; 50: 859–862
   PubMed Web of Science ®Google Scholar
• Horio Y., Takahashi T., Kuroishi T., Hibi K., Suyama M., Niimi T., Shimokata K., Yamakawa K., Nakamura Y., Ueda R., Takahashi T. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res. 1993; 53: 1–4
   PubMed Web of Science ®Google Scholar
• Wattel E., Preudhomme C., Hecquet B., Vanrumbeke M., Quesnel B., Dervite I., Morel P., Fenaux P. p53 mutations are associated with resistance to chemotherapy and short survival in hematological malignancies. Blood 1994; 84: 3148–3157
   PubMed Web of Science ®Google Scholar
• Montes de Oca Luna R., Wagner D.S., Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995; 378: 203–206
   PubMed Web of Science ®Google Scholar
• Jones S.N., Roe A.E., Donehower L.A., Bradley A. Rescue of early embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995; 378: 206–208
   PubMed Web of Science ®Google Scholar
• Cheng Y.X., Li Y.L., Wu J.D., Long S.B., Tzai T.S., Tzeng C.C., Lai M.D. Overexpression of MDM-2 mRNA and mutation of the p53 tumor suppressor gene in bladder carcinoma lines. Moleculor Carcinogenisis. 1995; 13: 173–181
   PubMed Web of Science ®Google Scholar
• Dubs-Poterszman M.C., Tocque B., Wasylyk B. MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest. Oncogene 1995; 11: 2445–2449
   PubMed Web of Science ®Google Scholar
• Xiao Z.X., Chen J., Levine A.J., Modjtahedl N., Xing J., Sellers W.R., Livingston D.M. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995; 375: 694–698
   PubMed Web of Science ®Google Scholar
• Martin K., Trouche D., Hagemeier C., Sorensen T.S., La Thangue N.B., Kouzarides T. Stimulation of E2F1/DP1 activity by MDM2 oncoprotein. Nature 1995; 375: 691–694
   PubMed Web of Science ®Google Scholar
• Yamasaki L., Jacks X., Branson R., Goillot E., Harlow E., Dyson N.J. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 1996; 85: 537–548
   PubMed Web of Science ®Google Scholar
• Field S.J., Tsai F-Y., Kuo F., Zubiaga A.M., Kaelin W.G., Jr., Livingston D.M., Orkin S.H., Greenberg M.E. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 1996; 85: 549–561
   PubMed Web of Science ®Google Scholar
• Maltzman W., Czyzyk U. V irradiation stimulates levels of the p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol. 1984; 4: 1689–1694
   PubMed Web of Science ®Google Scholar
• Olson D.C., Marechal V., Momand J., Chen J., Romocki C., Levine A.J. Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene 1993; 8: 2353–2360
   PubMed Web of Science ®Google Scholar
• Bueso-Ramos C.E., Manshouri T., Haidar M.A., Huh Y.O., Keating M.J., Albitar M. Multiple patterns of MDM-2 deregulation in human leukemias: Implication in leukemogenesis and prognosis. Leukemia und Lymphoma 1995; 17: 13–18
   PubMed Web of Science ®Google Scholar
• Maxwell S.A. Selective compartmentalization of different mdm2 proteins within the nucleus. Anticancer Res. 1994; 14: 2541–2548
   PubMed Web of Science ®Google Scholar
• Haines D.S., Landers J.E., Engle L.J., George D.L. Physical and functional interaction between wild-type p53 and mdm2 proteins. Mol. Cell. Biol. 1994; 41: 1171–1178
   Google Scholar
• Boddy M.N., Freemont P.S., Borden K.L. The p53-associated protein MDM2 contains a newly characterized zinc-binding domain called the RING finger. Trends in Biochemical Sciences 1994; 19: 198–199
   PubMed Web of Science ®Google Scholar